Boehringer Ingelheim Collaborates with Insilico on AI-Based Drug Discovery
Shots:
- The collaboration will utilize Insilico's generative ML technology and Pandomics discovery platform to identify potential therapeutic targets implicated in multiple diseases
- Insilico’s Pandomics platform will foster Boehringer’s capabilities to explore and identify drug targets and improves the drug discovery process contributing to human health
- In Jan 2020- Insilico Medicine allied with skincare firm Beiersdorf to discover bioactive ingredients for skin indications
Click here to read full press release/ article | Ref: PRNewswire | Image: Boehringer Ingelheim
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
